Immunocodex

Immunocodex is a biotechnology company developing tolerogenic mRNA vaccine therapies for the treatment of autoimmune diseases. The company has built a cutting-edge platform that uses novel mRNA constructs to induce antigen-specific immunomodulation, specifically targeting dendritic cells — powerful immune regulators that control the balance between pro-inflammatory and anti-inflammatory responses. By engaging immunomodulatory pathways including transcription factors and metabolic routes, Immunocodex's approach aims to reprogram the immune system at a cellular level, restoring immune balance without the broad suppression associated with conventional immunosuppressants. The company is headquartered in Boston, Massachusetts.